JP2019500428A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019500428A5 JP2019500428A5 JP2018550880A JP2018550880A JP2019500428A5 JP 2019500428 A5 JP2019500428 A5 JP 2019500428A5 JP 2018550880 A JP2018550880 A JP 2018550880A JP 2018550880 A JP2018550880 A JP 2018550880A JP 2019500428 A5 JP2019500428 A5 JP 2019500428A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- oligonucleotide
- disease
- oligonucleotide according
- dementia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims description 69
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 14
- 206010012289 Dementia Diseases 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 238000012986 modification Methods 0.000 claims description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 6
- 108020004999 messenger RNA Proteins 0.000 claims description 6
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 4
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 claims description 4
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 4
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 4
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 4
- 208000010577 Niemann-Pick disease type C Diseases 0.000 claims description 4
- 206010034010 Parkinsonism Diseases 0.000 claims description 4
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 4
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims description 4
- 229940104302 cytosine Drugs 0.000 claims description 4
- 208000017004 dementia pugilistica Diseases 0.000 claims description 4
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 2
- 206010059245 Angiopathy Diseases 0.000 claims description 2
- 208000014644 Brain disease Diseases 0.000 claims description 2
- 208000009093 Diffuse Neurofibrillary Tangles with Calcification Diseases 0.000 claims description 2
- 201000010374 Down Syndrome Diseases 0.000 claims description 2
- 208000032274 Encephalopathy Diseases 0.000 claims description 2
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 claims description 2
- 208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 claims description 2
- 206010072075 Gerstmann-Straussler-Scheinker syndrome Diseases 0.000 claims description 2
- 206010018341 Gliosis Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 206010061216 Infarction Diseases 0.000 claims description 2
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 2
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 2
- 102000029797 Prion Human genes 0.000 claims description 2
- 108091000054 Prion Proteins 0.000 claims description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims description 2
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 210000000349 chromosome Anatomy 0.000 claims description 2
- 230000007850 degeneration Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 210000000609 ganglia Anatomy 0.000 claims description 2
- 230000007387 gliosis Effects 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 201000008319 inclusion body myositis Diseases 0.000 claims description 2
- 230000007574 infarction Effects 0.000 claims description 2
- 206010027191 meningioma Diseases 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 150000004713 phosphodiesters Chemical class 0.000 claims description 2
- 230000000750 progressive effect Effects 0.000 claims description 2
- 230000002739 subcortical effect Effects 0.000 claims description 2
- 208000009999 tuberous sclerosis Diseases 0.000 claims description 2
- 208000024571 Pick disease Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 210000003710 cerebral cortex Anatomy 0.000 claims 1
- -1 dimethylaminoethyloxyethyl Chemical group 0.000 claims 1
- 201000005649 gangliocytoma Diseases 0.000 claims 1
- 201000008361 ganglioneuroma Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- HWPZZUQOWRWFDB-UHFFFAOYSA-N 1-methylcytosine Chemical compound CN1C=CC(N)=NC1=O HWPZZUQOWRWFDB-UHFFFAOYSA-N 0.000 description 1
- 201000007547 Dravet syndrome Diseases 0.000 description 1
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021076622A JP2021118732A (ja) | 2015-12-21 | 2021-04-28 | タウ発現を減少させるための組成物および方法 |
| JP2022021494A JP7594557B2 (ja) | 2015-12-21 | 2022-02-15 | タウ発現を減少させるための組成物および方法 |
| JP2024203529A JP2025026976A (ja) | 2015-12-21 | 2024-11-21 | タウ発現を減少させるための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562270165P | 2015-12-21 | 2015-12-21 | |
| US62/270,165 | 2015-12-21 | ||
| PCT/IB2016/057794 WO2017109679A1 (en) | 2015-12-21 | 2016-12-19 | Compositions and methods for decreasing tau expression |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021076622A Division JP2021118732A (ja) | 2015-12-21 | 2021-04-28 | タウ発現を減少させるための組成物および方法 |
| JP2022021494A Division JP7594557B2 (ja) | 2015-12-21 | 2022-02-15 | タウ発現を減少させるための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019500428A JP2019500428A (ja) | 2019-01-10 |
| JP2019500428A5 true JP2019500428A5 (OSRAM) | 2020-01-30 |
| JP7027328B2 JP7027328B2 (ja) | 2022-03-01 |
Family
ID=57758674
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018550880A Active JP7027328B2 (ja) | 2015-12-21 | 2016-12-19 | タウ発現を減少させるための組成物および方法 |
| JP2021076622A Pending JP2021118732A (ja) | 2015-12-21 | 2021-04-28 | タウ発現を減少させるための組成物および方法 |
| JP2022021494A Active JP7594557B2 (ja) | 2015-12-21 | 2022-02-15 | タウ発現を減少させるための組成物および方法 |
| JP2024203529A Pending JP2025026976A (ja) | 2015-12-21 | 2024-11-21 | タウ発現を減少させるための組成物および方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021076622A Pending JP2021118732A (ja) | 2015-12-21 | 2021-04-28 | タウ発現を減少させるための組成物および方法 |
| JP2022021494A Active JP7594557B2 (ja) | 2015-12-21 | 2022-02-15 | タウ発現を減少させるための組成物および方法 |
| JP2024203529A Pending JP2025026976A (ja) | 2015-12-21 | 2024-11-21 | タウ発現を減少させるための組成物および方法 |
Country Status (41)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013148260A1 (en) | 2012-03-30 | 2013-10-03 | Washington University | Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome |
| TW202246503A (zh) | 2013-07-19 | 2022-12-01 | 美商百健Ｍａ公司 | 用於調節τ蛋白表現之組合物 |
| JOP20190065A1 (ar) | 2016-09-29 | 2019-03-28 | Ionis Pharmaceuticals Inc | مركبات وطرق لتقليل التعبير عن tau |
| KR20200131263A (ko) * | 2018-03-13 | 2020-11-23 | 얀센 파마슈티카 엔.브이. | 변형 올리고뉴클레오티드 및 타우병증에서의 사용 방법 |
| CR20210178A (es) | 2018-07-03 | 2021-05-11 | Hoffmann La Roche | OLIGONUCLEÓTIDOS PARA MODULAR LA EXPRESIÓN DE TAU (Divisional 2021-0058) |
| KR20230005194A (ko) * | 2020-03-30 | 2023-01-09 | 알닐람 파마슈티칼스 인코포레이티드 | 미세소관 관련된 단백질 TAU (MAPT) iRNA 제제 조성물 및 이의 사용 방법 |
| CN113817728A (zh) * | 2020-06-19 | 2021-12-21 | 四川大学华西医院 | 一种有效干扰Tau蛋白表达的重组慢病毒及其应用 |
| US20240287518A1 (en) * | 2021-06-16 | 2024-08-29 | Empirico Inc. | Treatment of mtres1 related diseases and disorders |
| EP4370680A4 (en) * | 2021-07-16 | 2025-08-13 | Aptah Bio Inc | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR REGULATING GENE EXPRESSION |
| WO2024091874A1 (en) * | 2022-10-25 | 2024-05-02 | Empirico Inc. | Gene therapy treatment of mtres1 related diseases and disorders |
| WO2024155740A1 (en) * | 2023-01-18 | 2024-07-25 | Aptah Bio, Inc. | Polynucleotide compositions and methods for treatment of cancer |
| EP4652277A1 (en) * | 2023-01-18 | 2025-11-26 | Aptah Bio, Inc. | Polynucleotide compositions and methods for treatment of neurodegenerative diseases |
| WO2024220930A2 (en) * | 2023-04-20 | 2024-10-24 | Adarx Pharmaceuticals, Inc. | Mapt-modulating compositions and methods of use thereof |
| WO2025188990A1 (en) * | 2024-03-08 | 2025-09-12 | Eli Lilly And Company | Mapt antisense oligonucleotide |
| WO2025212467A1 (en) * | 2024-03-31 | 2025-10-09 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of microtubule associated protein tau (mapt), compositions thereof, and methods of use |
Family Cites Families (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| CA2073500C (en) | 1990-01-11 | 2008-03-25 | Phillip Dan Cook | Compositions and methods for detecting and modulating rna activity and gene expression |
| US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
| US5789573A (en) | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
| US20020052331A1 (en) | 1990-08-14 | 2002-05-02 | Brenda Baker | Compositions and methods for antisense inhibition of protein translation |
| DK0618968T3 (da) | 1991-12-06 | 2000-04-10 | Max Planck Gesellschaft | Midler til diagnostisering og behandling af Alzheimer's sygdom |
| US7408027B1 (en) | 1991-12-06 | 2008-08-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften | Tools for the diagnosis and treatment of Alzheimer's disease |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| AU680449B2 (en) * | 1992-10-05 | 1997-07-31 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of the ras gene |
| KR940021073A (ko) | 1993-03-02 | 1994-10-17 | 미야베 요시가즈 | 알쯔하이머병의 예방 또는 치료제, 그 스크리닝 방법 및 인간 유래의 타우 단백질 키나아제 i |
| CA2116460A1 (en) | 1993-03-02 | 1994-09-03 | Mitsubishi Chemical Corporation | Preventive or therapeutic agents for alzheimer's disease, a screening method of alzheimer's disease and tau-protein kinase i originated from human being |
| AU6786594A (en) | 1993-05-11 | 1994-12-12 | University Of North Carolina At Chapel Hill, The | Antisense oligonucleotides which combat aberrant splicing and methods of using the same |
| CA2749312A1 (en) | 1996-02-14 | 1997-08-21 | Novartis Ag | Sugar-modified gapped oligonucleotides |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| WO1999014226A2 (en) | 1997-09-12 | 1999-03-25 | Exiqon A/S | Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US20040186071A1 (en) | 1998-04-13 | 2004-09-23 | Bennett C. Frank | Antisense modulation of CD40 expression |
| JP2002513551A (ja) | 1998-05-01 | 2002-05-14 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | 病原性タウ突然変異 |
| US6664443B1 (en) | 1998-05-01 | 2003-12-16 | Mayo Foundation For Medical Education And Research | Pathogenic Tau mutations in transgenic mice |
| KR20010083111A (ko) * | 1998-07-14 | 2001-08-31 | 길리스 스티브 | 전립선암의 치료 및 진단을 위한 조성물 및 방법 |
| ATE287897T2 (de) | 1999-02-12 | 2005-02-15 | Sankyo Co | Analoga von nukleosiden und oligonukleotiden |
| US7084125B2 (en) | 1999-03-18 | 2006-08-01 | Exiqon A/S | Xylo-LNA analogues |
| US7098192B2 (en) * | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
| AU4471700A (en) | 1999-04-26 | 2000-11-10 | University Of North Carolina At Chapel Hill, The | Antisense human fucosyltransferase sequences and methods of use thereof |
| CN102180924A (zh) | 1999-05-04 | 2011-09-14 | 桑塔里斯制药公司 | L-核糖-lna类似物 |
| US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
| CN101284873A (zh) * | 1999-06-30 | 2008-10-15 | 科里克萨有限公司 | 用于肺癌治疗和诊断的组合物和方法 |
| JP4151751B2 (ja) | 1999-07-22 | 2008-09-17 | 第一三共株式会社 | 新規ビシクロヌクレオシド類縁体 |
| WO2001053340A2 (en) | 2000-01-21 | 2001-07-26 | Pharmacia & Upjohn Company | Transgenic mouse model of human neurodegenerative disease |
| EP1265999A2 (en) * | 2000-02-28 | 2002-12-18 | Decode Genetics EHF. | Human schizophrenia gene |
| WO2002055681A2 (en) | 2001-01-11 | 2002-07-18 | Bayer Ag | Regulation of human tau-tubulin kinase |
| US7569575B2 (en) | 2002-05-08 | 2009-08-04 | Santaris Pharma A/S | Synthesis of locked nucleic acid derivatives |
| US20050130924A1 (en) | 2002-06-26 | 2005-06-16 | Monia Brett P. | Antisense inhibition via RNAse H-independent reduction in mRNA |
| AU2003247521A1 (en) | 2002-06-26 | 2004-01-19 | Isis Pharmaceuticals, Inc. | Antisense inhibition via rnase h-independent reduction in mrna |
| US20040241854A1 (en) | 2002-08-05 | 2004-12-02 | Davidson Beverly L. | siRNA-mediated gene silencing |
| US20080176812A1 (en) | 2002-08-05 | 2008-07-24 | Davidson Beverly L | Allele-specific silencing of disease genes |
| US20050106731A1 (en) | 2002-08-05 | 2005-05-19 | Davidson Beverly L. | siRNA-mediated gene silencing with viral vectors |
| JP4393382B2 (ja) | 2002-08-14 | 2010-01-06 | 三菱化学株式会社 | 中枢性タウ蛋白質特異的抗体 |
| AU2003291753B2 (en) | 2002-11-05 | 2010-07-08 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| US7250496B2 (en) * | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| US7906326B2 (en) | 2003-05-07 | 2011-03-15 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides associated with alzheimer's disease and uses thereof |
| US8163896B1 (en) | 2002-11-14 | 2012-04-24 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| US20060257851A1 (en) | 2002-11-26 | 2006-11-16 | Itzhak Bentwich | Bioinformatically detectable group of novel viral regulatory genes and uses thereof |
| US7790867B2 (en) | 2002-12-05 | 2010-09-07 | Rosetta Genomics Inc. | Vaccinia virus-related nucleic acids and microRNA |
| US20070077553A1 (en) | 2003-10-30 | 2007-04-05 | Rosetta Genomics | Bioinformatically detectable group of novel vaccinia regulatory genes and uses thereof |
| US20130130231A1 (en) | 2002-11-26 | 2013-05-23 | Isaac Bentwich | Bioinformatically detectable group of novel viral regulatory genes and uses thereof |
| US7696334B1 (en) | 2002-12-05 | 2010-04-13 | Rosetta Genomics, Ltd. | Bioinformatically detectable human herpesvirus 5 regulatory gene |
| US7888497B2 (en) | 2003-08-13 | 2011-02-15 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof |
| AU2003904328A0 (en) | 2003-08-13 | 2003-08-28 | Garvan Institute Of Medical Research | Diagnosis and treatment of neurodegenerative disorders |
| EP2489737A1 (en) | 2003-08-28 | 2012-08-22 | Novartis AG | Interfering RNA duplex having blunt-ends and 3'-modifications |
| US20070106066A1 (en) | 2003-10-28 | 2007-05-10 | Alexander Cherkasky | Cherkasky fusion proteins containing antibody-, antigen- and microtubule-binding regions and immune response-triggering regions |
| US20050244851A1 (en) | 2004-01-13 | 2005-11-03 | Affymetrix, Inc. | Methods of analysis of alternative splicing in human |
| CA2566519C (en) * | 2004-05-14 | 2020-04-21 | Rosetta Genomics Ltd. | Micrornas and uses thereof |
| US7687616B1 (en) | 2004-05-14 | 2010-03-30 | Rosetta Genomics Ltd | Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof |
| USRE47769E1 (en) | 2004-06-28 | 2019-12-17 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| US7312035B2 (en) | 2004-09-03 | 2007-12-25 | Affymetrix, Inc. | Methods of genetic analysis of yeast |
| US7838657B2 (en) | 2004-12-03 | 2010-11-23 | University Of Massachusetts | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
| US7833513B2 (en) | 2004-12-03 | 2010-11-16 | Rhode Island Hospital | Treatment of Alzheimer's Disease |
| CA2587601C (en) | 2004-12-03 | 2017-11-07 | Rhode Island Hospital | Diagnosis and treatment of alzheimer's disease |
| US20070048756A1 (en) | 2005-04-18 | 2007-03-01 | Affymetrix, Inc. | Methods for whole genome association studies |
| US8501703B2 (en) | 2005-08-30 | 2013-08-06 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds for modulation of splicing |
| WO2007047913A2 (en) | 2005-10-20 | 2007-04-26 | Isis Pharmaceuticals, Inc | Compositions and methods for modulation of lmna expression |
| GB0605337D0 (en) | 2006-03-17 | 2006-04-26 | Genomica Sau | Treatment of CNS conditions |
| US7901882B2 (en) | 2006-03-31 | 2011-03-08 | Affymetrix, Inc. | Analysis of methylation using nucleic acid arrays |
| CA3024953A1 (en) | 2006-04-03 | 2007-10-11 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| US20090280110A1 (en) | 2006-06-27 | 2009-11-12 | University Of Virginia Patent Foundation | Cell Model for Alzheimer's Disease Pathology |
| US20100021914A1 (en) | 2006-11-23 | 2010-01-28 | Querdenker Aps | Oligonucleotides for modulating target rna activity |
| EP2578692B1 (en) | 2007-04-05 | 2016-06-08 | The J. David Gladstone Institutes | Agents that reduce neuronal overexcitation |
| JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
| WO2009109665A1 (en) | 2008-03-07 | 2009-09-11 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
| JP5773535B2 (ja) | 2009-04-24 | 2015-09-02 | ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ | インターフェロンに非応答性のｈｃｖ患者の治療のための医薬組成物 |
| WO2011057350A1 (en) | 2009-11-12 | 2011-05-19 | The University Of Western Australia | Antisense molecules and methods for treating pathologies |
| US20150018223A1 (en) | 2010-01-28 | 2015-01-15 | University Of Massachusetts Lowell | Methods of diagnosing tau-associated neurodegenerative diseases |
| US20130079505A1 (en) | 2010-03-24 | 2013-03-28 | Mirrx Therapeutics A/S | Bivalent antisense oligonucleotides |
| EP3260540A1 (en) | 2010-11-12 | 2017-12-27 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
| EP2643341A4 (en) | 2010-11-23 | 2014-08-27 | Mirrx Therapeutics As | Oligonucleotides for modulating a TARGET RNA activity |
| EP2655621B1 (en) | 2010-12-20 | 2018-05-23 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
| US9957558B2 (en) * | 2011-04-28 | 2018-05-01 | Life Technologies Corporation | Methods and compositions for multiplex PCR |
| WO2013013165A2 (en) | 2011-07-21 | 2013-01-24 | The Trustees Of The University Of Pennsylvania | Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus |
| WO2013148260A1 (en) | 2012-03-30 | 2013-10-03 | Washington University | Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome |
| AU2013243954A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| EP2855520B1 (en) | 2012-06-04 | 2018-09-26 | Novartis AG | Site-specific labeling methods and molecules produced thereby |
| CN104936977B (zh) | 2012-10-24 | 2019-10-08 | 开普敦大学 | 微管修饰化合物 |
| US9200068B2 (en) | 2012-12-18 | 2015-12-01 | Regents Of The University Of Minnesota | Compositions and methods related to tauopathy |
| BR112015014987A2 (pt) | 2012-12-20 | 2017-08-15 | Sarepta Therapeutics Inc | Aprimoradas composições que pulam éxon para o tratamento da distrofia muscular |
| US9217148B2 (en) | 2013-03-14 | 2015-12-22 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
| SMT201900139T1 (it) | 2013-03-14 | 2019-05-10 | Sarepta Therapeutics Inc | Composizioni di salto dell'esone per il trattamento della distrofia muscolare |
| MX2015012621A (es) * | 2013-03-14 | 2016-05-31 | Ionis Pharmaceuticals Inc | Composiciones y metodos para modular la expresion de tau. |
| JP7011389B2 (ja) | 2013-06-12 | 2022-01-26 | オンコイミューニン，インコーポレイティド | オリゴヌクレオチドの全身性イン－ビボ送達 |
| TW202246503A (zh) * | 2013-07-19 | 2022-12-01 | 美商百健Ｍａ公司 | 用於調節τ蛋白表現之組合物 |
| WO2015068075A2 (en) | 2013-10-24 | 2015-05-14 | Institut National De La Sante Et De La Recherche Medicale | Detection of tau |
| WO2016011123A1 (en) * | 2014-07-16 | 2016-01-21 | Arrowhead Research Corporation | Organic compositions to treat apoc3-related diseases |
| WO2016019063A1 (en) | 2014-07-29 | 2016-02-04 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating tau expression |
| PE20171766A1 (es) | 2015-02-04 | 2017-12-21 | Hoffmann La Roche | Oligomeros antisentido de tau y usos de estos |
| WO2016127002A1 (en) | 2015-02-04 | 2016-08-11 | Bristol-Myers Squibb Company | Lna oligonucleotides with alternating flanks |
| EP3254104B1 (en) | 2015-02-04 | 2021-08-25 | Bristol-Myers Squibb Company | Methods of selecting therapeutic molecules |
| US20170035860A1 (en) * | 2015-04-02 | 2017-02-09 | Alexander C. Flynn | Compositions and methods for treatment of neurogenerative diseases |
-
2015
- 2015-12-21 JO JOP/2020/0228A patent/JOP20200228A1/ar unknown
-
2016
- 2016-12-19 KR KR1020257023205A patent/KR20250112919A/ko active Pending
- 2016-12-19 IL IL305866A patent/IL305866B2/en unknown
- 2016-12-19 MA MA44426A patent/MA44426B1/fr unknown
- 2016-12-19 NZ NZ783034A patent/NZ783034A/en unknown
- 2016-12-19 MX MX2018007726A patent/MX2018007726A/es unknown
- 2016-12-19 CN CN202211714988.9A patent/CN116218848A/zh active Pending
- 2016-12-19 CA CA3008094A patent/CA3008094A1/en active Pending
- 2016-12-19 MA MA71468A patent/MA71468A/fr unknown
- 2016-12-19 TW TW111120037A patent/TWI834177B/zh active
- 2016-12-19 PE PE2023001204A patent/PE20241069A1/es unknown
- 2016-12-19 DK DK16823350.0T patent/DK3394259T3/da active
- 2016-12-19 IL IL296844A patent/IL296844B2/en unknown
- 2016-12-19 SI SI201631822T patent/SI3394259T1/sl unknown
- 2016-12-19 JP JP2018550880A patent/JP7027328B2/ja active Active
- 2016-12-19 LT LTEPPCT/IB2016/057794T patent/LT3394259T/lt unknown
- 2016-12-19 CU CU2018000065A patent/CU24574B1/es unknown
- 2016-12-19 ES ES16823350T patent/ES2984631T3/es active Active
- 2016-12-19 HR HRP20240672TT patent/HRP20240672T1/hr unknown
- 2016-12-19 EA EA201891468A patent/EA036417B1/ru not_active IP Right Cessation
- 2016-12-19 EA EA202091865A patent/EA202091865A1/ru unknown
- 2016-12-19 CR CR20200609A patent/CR20200609A/es unknown
- 2016-12-19 SG SG11201804704PA patent/SG11201804704PA/en unknown
- 2016-12-19 PT PT168233500T patent/PT3394259T/pt unknown
- 2016-12-19 PE PE2018001176A patent/PE20181448A1/es unknown
- 2016-12-19 RU RU2018126545A patent/RU2747734C2/ru active
- 2016-12-19 HU HUE16823350A patent/HUE066548T2/hu unknown
- 2016-12-19 EP EP24154346.1A patent/EP4406541A3/en not_active Withdrawn
- 2016-12-19 JO JOP/2016/0266A patent/JO3790B1/ar active
- 2016-12-19 US US15/383,452 patent/US11473083B2/en active Active
- 2016-12-19 UY UY0001037038A patent/UY37038A/es active IP Right Grant
- 2016-12-19 CN CN201680082326.0A patent/CN109072237B/zh active Active
- 2016-12-19 WO PCT/IB2016/057794 patent/WO2017109679A1/en not_active Ceased
- 2016-12-19 PL PL16823350.0T patent/PL3394259T3/pl unknown
- 2016-12-19 MY MYPI2018702190A patent/MY191737A/en unknown
- 2016-12-19 KR KR1020187020632A patent/KR102834468B1/ko active Active
- 2016-12-19 FI FIEP16823350.0T patent/FI3394259T3/fi active
- 2016-12-19 RS RS20240565A patent/RS65535B1/sr unknown
- 2016-12-19 AR ARP160103917A patent/AR107579A1/es unknown
- 2016-12-19 AU AU2016376034A patent/AU2016376034B2/en active Active
- 2016-12-19 PH PH1/2018/501207A patent/PH12018501207B1/en unknown
- 2016-12-19 NZ NZ743231A patent/NZ743231A/en unknown
- 2016-12-19 TW TW105142107A patent/TWI787163B/zh active
- 2016-12-19 EP EP16823350.0A patent/EP3394259B1/en active Active
- 2016-12-19 SG SG10201913434PA patent/SG10201913434PA/en unknown
-
2018
- 2018-06-01 ZA ZA2018/03661A patent/ZA201803661B/en unknown
- 2018-06-18 SV SV2018005714A patent/SV2018005714A/es unknown
- 2018-06-18 CO CONC2018/0006297A patent/CO2018006297A2/es unknown
- 2018-06-18 CL CL2018001652A patent/CL2018001652A1/es unknown
- 2018-06-18 IL IL260124A patent/IL260124A/en unknown
- 2018-06-19 SA SA518391831A patent/SA518391831B1/ar unknown
- 2018-06-20 DO DO2018000151A patent/DOP2018000151A/es unknown
- 2018-06-21 MX MX2023008211A patent/MX2023008211A/es unknown
- 2018-07-05 EC ECSENADI201850575A patent/ECSP18050575A/es unknown
-
2019
- 2019-01-18 CL CL2019000149A patent/CL2019000149A1/es unknown
- 2019-11-25 CL CL2019003420A patent/CL2019003420A1/es unknown
-
2020
- 2020-11-13 AU AU2020267282A patent/AU2020267282B2/en active Active
-
2021
- 2021-04-28 JP JP2021076622A patent/JP2021118732A/ja active Pending
-
2022
- 2022-02-15 JP JP2022021494A patent/JP7594557B2/ja active Active
- 2022-07-20 US US17/813,843 patent/US20220411796A1/en active Pending
-
2024
- 2024-11-21 JP JP2024203529A patent/JP2025026976A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019500428A5 (OSRAM) | ||
| FI3394259T3 (fi) | Koostumuksia ja menetelmiä tau:n ilmentymisen vähentämiseksi | |
| JP2016533717A5 (OSRAM) | ||
| JP2016533751A5 (OSRAM) | ||
| JP2015536132A5 (OSRAM) | ||
| JP2020022483A5 (OSRAM) | ||
| JP2021072840A5 (OSRAM) | ||
| JP2016116520A5 (OSRAM) | ||
| JP2013525330A5 (OSRAM) | ||
| JP2015516953A5 (OSRAM) | ||
| JP2012050438A5 (OSRAM) | ||
| JP2016530882A5 (OSRAM) | ||
| RU2019130898A (ru) | Композиции для модуляции экспрессии атаксина 2 | |
| JP2017510271A5 (OSRAM) | ||
| JP2005517436A5 (OSRAM) | ||
| JP2019529489A5 (OSRAM) | ||
| JP2016520310A5 (OSRAM) | ||
| JP2020511155A5 (OSRAM) | ||
| JP2015532097A5 (OSRAM) | ||
| JP2021515784A (ja) | 修飾オリゴヌクレオチド及びタウオパチーにおける使用方法 | |
| JP2021505129A5 (OSRAM) | ||
| CN118910063A (zh) | 包含修饰核苷的寡核苷酸 | |
| JP2013537404A5 (OSRAM) | ||
| RU2020125769A (ru) | Олигонуклеотиды для модуляции экспрессии tmem106b | |
| JP2020521491A5 (OSRAM) |